Health
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC – OncLive
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation…
Because no standard approaches exist for patients with EGFR-mutated nonsmall cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially…
-
Noosa News16 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
Noosa News24 hours agoIpswich landmark shuts down after 50 years due to storms, costs and lack of new movies
-
Noosa News19 hours agoFuel tanker racing to unload in Darwin ahead of Tropical Cyclone Fina
-
Noosa News17 hours agoShattered families demand justice after Wieambilla killers not deemed terrorists